Overview

This course trains regulatory professionals in how to communicate strategically and effectively with the U.S. Food and Drug Administration (FDA), especially in the context of medical device development. While the FDA is not a negotiator in the conventional sense, interactions with the Agency require scientific framing, structured reasoning, and ethical persuasion. Through real-world scenarios, document analysis, and structured assignments, learners will develop the judgment needed to prepare for pre-submission meetings, frame effective regulatory questions, respond to inspections or enforcement actions, and escalate disagreements professionally and appropriately. The course emphasizes the FDA's public health mission, legal boundaries, and internal review logic, focusing on what can be influenced, what cannot, and how to operate effectively within that structure.

Syllabus

FDA Is Not a Negotiator — But Judgment Is Required

Welcome to the Communicating and Negotiating with FDA: Medical Devices course! Module 1 establishes the FDA's role as a law-driven regulator committed to public health protection, not a traditional negotiating partner in product approval. It details how to apply risk-based classification to medical devices to determine the correct regulatory pathway. The module also provides strategies for effective, judgment-informed communication to meet evidentiary standards within the FDA’s legal framework.

Communication as Strategy

Module 2 views communication with the FDA as a core regulatory strategy, where clarity in framing issues and requests directly impacts the efficiency and outcome of interactions. We will focus on structuring clear written and verbal communication, preparing for meetings, and advocating constructively to create a well-supported path toward regulatory alignment.

Preparing for FDA Meetings — Internal and External

This module reframes these interactions not as conversations, but as high-stakes, formal decision events that dictate your product's regulatory trajectory. It emphasizes that because these interactions are often a "one-shot" reality, successful preparation must focus on achieving internal alignment, designing conditional questions that the FDA can answer, and controlling risk in a constrained environment.

FDA Inspections in the QMSR Era — BIMO, OII, and Enforcement Response

Module 4 addresses managing the high-stakes negotiation of an FDA inspection in the medical device industry. It focuses on how the new Quality System Management Regulation (QMSR) and the Office of Inspections and Investigations (OII) have fundamentally changed the rules of engagement. We will learn to manage the inspection narrative, emphasizing disciplined communication.

Dispute Resolution, Crisis Planning, and Advisory Committee Meetings

Module 5 explores three high-stakes areas of FDA communication and negotiation: dispute resolution, regulatory crisis management, and preparation for FDA Advisory Committee meetings. The module details both formal and informal pathways for breaking impasses, strategies for managing crises with transparency and accountability, and the rigorous planning required for a successful public expert review.